Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia

Leukemia, T Cell Clinical Trial

Official title: Cell Therapy for CD7 Positive Acute Leukemia or Mixed Lineage Leukemia Except Those Who Are Diagnosed With T-ALL/T-LBL Using CD7-Specific CAR-T Cells

Status Completed

Clinical Trial Summary

This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T cell in the treatment of CD7 Positive acute leukemia or mixed lineage leukemia except those who are diagnosed with T-ALL/T-LBL

Clinical Trial Description

The CARs consist of an anti-CD7 VHHs, a portion of the human CD137（4-1BB） molecule, and the intracellular component of the human CD3ζ molecule. Prior to CAR-T cell infusion, the patients will be subjected to preconditioning treatment. After CAR-T cell infusion, the patients will be evaluated for adverse reactions and efficacy.

The Main research objectives:

To evaluate the safety and efficacy of CD7 CAR-T cells in patients with CD7 Positive acute leukemia or mixed lineage leukemia except those who are diagnosed with T-ALL/T-LBL

The Secondary research objectives:

To investigate the cytokinetic characteristics of CD7 CAR-T cells in patients with CD7 Positive acute leukemia or mixed lineage leukemia except those who are diagnosed with T-ALL/T-LBL ;

Related Conditions & MeSH terms

• Leukemia
• Leukemia, T Cell
• Leukemia, T-Cell

• NCT number: NCT04938115
• Study type: Interventional
• Source: Hebei Senlang Biotechnology Inc., Ltd.
• Status: Completed
• Phase: N/A
• Start date: May 10, 2021
• Completion date: October 30, 2023